Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-17T00:31:01.881Z Has data issue: false hasContentIssue false

Aztreonam

Published online by Cambridge University Press:  21 June 2016

Allan R. Tunkel*
Affiliation:
Departments of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia

Extract

Aztreonam, the first licensed monobactam in the United States, is a β-lactam antimicrobial agent with a unique structure and in vitro spectrum of activity. The drug is active only against gram-negative aerobic bacteria in vitro, thus resembling the spectrum of aminoglycosides, but displays the safety profile typical of β-lactam agents. Due to these properties, aztreonam may prove useful in the therapy of various nosocomial infections. This review outlines the salient features of aztreonam and suggests areas of appropriate usage.

Information

Type
Special Section
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1990 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable